Faron is a clinical stage biopharmaceutical company developing novel treatments for medical conditions with significant unmet needs. Its lead program is bexmarilimab, its investigative precision immunotherapy in Phase I/II development as a novel macrophage checkpoint immunotherapy for patients with hematological malignancies. Bexmarilimab is a novel anti-Clever-1 antibody with the ability to switch immune suppression to immune activation. Faron is based in Turku, Finland and Boston, Massachusetts. Faron is listed on AIM under the ticker ‘FARN’ and Nasdaq First North Growth Market ("Nasdaq First North") under ticker FARON.
Looking for a particular Faron employee's phone or email?
Faron Questions
The Faron annual revenue was $6.5 million in 2026.
Juho Jalkanen is the CEO of Faron.
27 people are employed at Faron.
Faron is based in Turku, Southwest Finland.
The NAICS codes for Faron are [3254, 325, 32, 32541].
The SIC codes for Faron are [873, 28, 87, 283].
Top Faron Employees
-
12
-
3
-
Ralph Hughes
Chief Business Officer at Faron
Madrid, ES21 -
Marita Vainio
VP, CMC at Faron
Turku, FI2 -
Joab Williamson
VP Operations at Faron
Manchester, England, GB41 -
Vesa Karvonen
General Counsel at Faron
Espoo, FI22 -
2
-
Aneel Nimba
Medical Director at Faron
London, GB1
Related Companies
